U.S. firm with ex-military ties plots entry into Africa's top copper-producing nation
A consortium of American investors and former US military personnel is negotiating to acquire a major mineral producer in the DRC
Orion Resource Partners and Virtus Minerals are key players in the deal, with Virtus proposing to manage operations and Orion providing financial backing.
This acquisition aligns with a broader US strategy to reduce China's dominance in the global critical minerals market, particularly within Africa.
The negotiations, involving Orion Resource Partners and Virtus Minerals, reflect a broader push by the United States under President Donald Trump to counter China's dominant position in the critical minerals market, especially in Africa.
The US-owned firms have deep ties to the US military and intelligence community, with expertise in critical mineral supply chains.
Orion, based in New York, manages around $8 billion in mining-related assets, while Virtus operates a Congolese subsidiary, ROK Metals.
Virtus President Gregory Roberts previously served with the CIA and the House Intelligence Committee, and Managing Director Phil Braun is a Green Beret with two decades of military experience.
Under the proposed deal, Orion would finance the acquisition and Virtus would oversee operations. Financial details remain undisclosed.
However, Bloomberg reports that a source familiar with the negotiations says the parties have not yet entered into an exclusivity agreement, as several aspects of the deal remain unresolved.
US's deep interest in Congo's minerals
As the world's second-largest producer of copper and the leading source of cobalt, the central African nation has become a strategic focus in Washington's push to counter China's dominance over global critical mineral supply chains.
The talks are unfolding amid efforts by President Donald Trump's administration to strengthen American involvement in the Democratic Republic of Congo's mining sector.
They are also seen as part of a broader strategy to ease the long-standing tensions between the DRC and Rwanda, disputes that have been deeply rooted in the struggle over control of the region's vast mineral wealth.
Chemaf, which operates significant mining assets across the DRC, is one of Congo's most prominent producers of cobalt, an essential metal for batteries and electric vehicles as well as copper, which structures everything from power grids to electronics.
With Congo being the world's largest cobalt supplier and second-largest copper producer, control over Chemaf offers enormous geopolitical and economic leverage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


News24
29 minutes ago
- News24
Volkswagen takes R27bn global hit from Trump tariffs
For more financial news, go to the News24 Business front page. German auto giant Volkswagen said Friday that tariffs imposed by US President Donald Trump had cost it 1.3 billion (R27 billion) euros in the first half of the year as it reported falling profit. Overall net profit fell 38.5 percent year-on-year during the period to hit 7.28 billion euros (R150 billion). Higher-sales of lower-margin electric vehicles (EVs) as well as restructuring costs hit the result in addition to the tariffs, Volkswagen said. Finance chief Arno Antlitz said Volkswagen was nevertheless "on the right track" and that performance was at the "upper end of expectations", if tariffs and restructuring costs are excluded. The firm struck an unprecedented deal with unions last December to cut 35 000 jobs in Germany by 2030 as part of plans to save 15 billion euros a year. The 10-brand group also cut its revenue and profit outlook, warning of "political uncertainty and increased barriers to trade" for the remainder of the year. It now forecasts a profit margin for the year of between 4 and 5 percent, down from 5.5 to 6.5 percent previously, amounting to billions of euros for the firm. The range assumes that the United States will continue to levy tariffs of 10 percent on imported cars in the best case and stick to its current rate of 27.5 percent in the worst, Volkswagen said. Volkswagen's previous guidance, released in April shortly after new US tariffs took effect, did not take the increased duties into account. Sales by volume in North America fell 16 percent "mainly due to tariffs" in the first half even as they rose slightly worldwide, Volkswagen said. Trump in April slapped an additional 25-percent levy on imported cars as part of an aggressive trade policy he says will help boost US manufacturing. That has hit European carmakers. French group Stellantis - whose brands include Jeep, Citroen and Fiat - said on Monday that North American vehicle sales by volume plunged 25 percent in the second quarter of the year. US and European Union diplomats are currently negotiating ahead of the latest deadline set by Trump, with Trump threatening a blanket duty of 30 percent after August 1 if no agreement is reached.
Yahoo
an hour ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Solve the daily Crossword